). Expression quantitative trait locus analysis in normal breast tissues and breast tumors showed that the g (risk) allele of rs10941679 was associated with increased expression of FGF10 and MRPS30. Functional assays demonstrated that SNP rs10941679 maps to an enhancer element that physically interacts with the FGF10 and MRPS30 promoter regions in breast cancer cell lines. FGF10 is an oncogene that binds to FGFR2 and is overexpressed in~10% of human breast cancers, whereas MRPS30 plays a key role in apoptosis. These data suggest that the strongest signal of association at 5p12 is mediated through coordinated activation of FGF10 and MRPS30, two candidate genes for breast cancer pathogenesis.
centromeric; r 2 ¼ 0.18). 3 A subsequent study, using 22
SNPs in~5,000 case subjects and~33,000 control subjects of European ancestry, reported that risk at this locus could be explained by two SNPs: rs4415084 and rs10941679. 4 More recently, a BCAC study confirmed that rs10941679 was associated with risk of lower-grade, progesterone receptor (PGR [MIM: 607311])-positive breast cancer tumors. 5 Here, we report the comprehensive fine-scale mapping of this locus in 104,660 subjects from 50 case-control studies participating in BCAC, including 41 studies from populations of European ancestry and nine of East Asian ancestry, and we explore the functional mechanisms underlying the associations in this region. Genotyping was conducted with the COGS array, a custom array comprising approximately 200,000 SNPs. 6 After quality- Table S1 ). SNP rs10941679 showed the strongest overall association (MAF ¼ 0.27, per-minor (g) allele: OR ¼ 1.12; 95% CI 1.10-1.14; p ¼ 2.55 3 10 À26 ; Figure 1 , Tables 1 and S1 ).
To identify additional association signals at this region, we conducted a forward stepwise logistic regression examining SNPs with univariate p < 0.1 (n ¼ 1,040 Haplotype analyses were conducted using the above three signal-representative variants, which generated eight haplotypes ( Table 2 ). Haplotypes carrying the rare allele of signal 3 SNP rs200229088 conferred higher risks than corresponding haplotypes carrying the common allele, consistent with this allele having an independent effect. Haplotype G, carrying the minor alleles of both the signal 1 and 2 representative SNPs, is very rare and reveals that their risk alleles are negatively correlated, which is also consistent with our finding that signal 2 top SNP rs6864776 increases in significance after conditioning on signal 1 SNP rs10941679 (Table 1) .
We examined the associations of these three SNPs in the Asian case-control studies within BCAC. SNP1 and SNP3 both replicated in the Asian studies and the relative risk estimates with overall breast cancer were consistent with those seen in the European population: per g-allele OR (rs10941679) ¼ The purple dotted line intersects the y axis at p ¼ 10 À8 and indicates genome-wide significance. Candidate SNPs in signal 1 (rs10941679), signal 2 (38 SNPs), and signal 3 (rs200229088) are shown as short vertical lines. The locations of annotated genes and putative lncRNA transcripts from GENCODE and enhancers predicted in Corradin et al. 13 and Hnisz et al. 12 from breast cancer cell lines are shown in the bottom panels. Table S4 ). Although the number of ER þ breast cell lines carrying the risk allele was limited, FGF10 and MRPS30 mRNA levels were significantly higher in the BT474 heterozygous cell line ( Figures 2C and 2D ). BRCAT54 was detected in the majority of cell lines but its expression appears to be genotype independent ( Figure S3A ). FGF10-AS1, RP11-503D12.1, and RP11-473L15.3 transcripts were either expressed at very low levels or not detected in the cell lines analyzed ( Figures  S3B-S3D ). Therefore, although we cannot rule out the possibility that the risk SNPs may influence local lncRNA expression, the low or absent transcript levels precluded any further evaluation. Candidate causal SNPs were then explored using publicly available datasets from ENCODE, 11 which includes information such as the location of promoter and enhancer histone marks, open chromatin, bound proteins, and altered motifs for the MCF7 breast cancer cell line, and from Hnisz et al. 12 and Corradin et al. 13 to identify the location of likely enhancers and their gene targets in a cell-specific context. Analysis of cis enhancer-gene interactions via PreSTIGE 13 showed evidence of putative regulatory elements (PREs) surrounding the top risk-associated SNPs in MCF7 breast cancer cells, but no histonemarked elements harboring a risk SNP in this cell line or in a range of cell lines and tissues analyzed in Roadmap (Figures 1 and S4 ). However, it is possible that certain epigenetic marks may be detected only in a specific cell subtype such as breast stem cells or in response to an external stimulus. 
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Each haplotype was compared to the ancestral haplotype carrying the common alleles of signal 1 SNP rs10941679, signal 2 SNP rs6864776, and signal 3 SNP rs200229088 (haplotype A).
To identify target gene(s), we performed chromatin conformation capture (3C) assays in ER þ MCF7, BT474, and MDA-MB-361 and ER À MDA-MB-231 breast cancer cell lines and Bre80 normal breast cells (Table S5) . 8 3C libraries were created by cross-linking the chromatin from cell lines; DNA was then digested with EcoRI, which flanks 12 contiguous fragments that cover the PRE, and the FGF10, MRPS30, and HCN1 promoters (Table S6) ; DNA was religated and decrosslinked; and qPCR with primers for the bait (gene promoters) and interactors (12 PRE fragments) was performed to detect the presence of ligation products, representing gene loops. BAC clones covering the regions of interest were used to normalize for PCR efficiency. These assays showed that the PRE containing SNP1 frequently interacted with the FGF10 and MRPS30 promoter regions in MCF7 and BT474 breast cancer cell lines, but only with MRPS30 in the MDA-MB-361, MDA-MB-231, and Bre80 cell lines. This latter result was expected because FGF10 is not expressed or expressed at very low levels in these cell lines ( Figures 2C, 3A , S5, and S6). Notably, both genes share a bidirectional promoter with the lncRNAs FGF10-AS1 and BRCAT54, raising the possibility that these transcripts are also targets of the PRE ( Figure 3A) . No additional interactions were detected between the PRE and other annotated genes within 1 Mb of the PRE, including HCN1 ( Figure S5 ). To assess the potential impact of SNP1 on the identified chromatin interactions, allele-specific 3C was performed in heterozygous BT474 cell lines. 8 However, the sequence profiles revealed that SNP1 had no significant effect on chromatin looping ( Figure S7 ). The regulatory capability of the PRE, combined with the effect of SNP1, was further examined in reporter assays. Promoter-driven luciferase reporter constructs were generated by the insertion of PCR-amplified fragments containing FGF10, FGF10-AS1, MRPS30, or BRCAT54 promoters into pGL3-Basic.
14 A 1,736-bp PRE fragment (containing either the common or minor allele of rs10941679) was then generated by PCR and cloned downstream of the modified pGL3-promoter constructs (Table S7 ). MCF7 and BT474 breast cancer cell lines plus Bre80 normal breast cells were transfected with the reporter plasmids and luciferase activity was measured 24 hr after transfection.
To correct for any differences in transfection efficiency or cell lysate preparation, Firefly luciferase activity was normalized to Renilla. Notably, the ''Ref PRE'' acted as a transcriptional enhancer, leading to a 2-to 3-fold increase in FGF10, MRPS30, and BRCAT54 promoter activity, but had no effect on the FGF10-AS1 promoter in MCF7 and BT474 cells (Figures 3B and S8 ). The enhancer activity was also observed for the MRPS30 and BRCAT54 promoters in Bre80 cells ( Figure S8 ). In all cell lines, inclusion of the SNP1 risk (g) allele had no significant effect on the PRE enhancer activity. Although this appears to rule out an effect of this SNP on transactivation, it is possible that SNP1 affects the recruitment of key proteins required for the epigenetic modification of the enhancer, which would not be observed in a reporter assay. Another possibility is that the SNP effect may be observed only under certain biological conditions such as growth factor stimulation.
To seek further evidence that SNP1 lies within an enhancer element, we performed electrophoretic mobility shift assays (EMSAs) for both the protective (a) and risk (g) alleles.
15 Nuclear lysates were prepared from ER þ BT474, MCF7, and MDA-MB-361 or ER À MDA-MB-231 and
Hs578T cells using the NE-PER nuclear and cytoplasmic extraction reagents. Biotinylated oligonucleotide duplexes were prepared by combining sense and antisense oligonucleotides, heat annealing, and slow cooling. Duplex-bound complexes were transferred onto Zeta-Probe positively charged nylon membranes by semi-dry transfer then cross-linked onto the membranes. Membranes were processed with the LightShift Chemiluminescent EMSA kit as per the manufacturer's instructions, and signals were visualized with the C-DiGit blot scanner. For SNP1, we observed allele-specific binding by nuclear proteins only in the ER þ BT474, MCF7, and MDA-MB-361 extracts (Figures 3C and S9 ). The protein-DNA complexes were shown to be specific, as demonstrated by increasing amounts of cold self-competitor (Figures 3C and S9 and Table S8 ). Table S7 . Error bars denote 95% confidence intervals from three independent experiments. p values were determined by 2-way ANOVA followed by Dunnett's multiple comparisons test (***p < 0.001). (C) EMSA for oligonucleotides containing SNP rs1094617 with the A ¼ common allele and G ¼ minor allele as indicated below the panel, assayed using BT474 nuclear extracts. Primers are listed in Table S8 . Labels above each lane indicate inclusion of competitor oligonucleotides at 30-and 100-fold molar excess, respectively: (-) no competitor and control denotes a non-specific competitor. A red arrowhead shows a band of different mobility detected between the common and minor alleles.
Further EMSAs using competitor DNA or antibody supershifts against predicted transcription factors (TFs) suggested four proteins bound to the SNP site including FOXA1, FOXA2, CEBPB, and OCT1 ( Figure S10 and Table  S9 ). To confirm TF binding in vivo, we performed chromatin immunoprecipitation (ChIP) in heterozygous BT474 cells as previously described (Table S10) . 15 When compared to an IgG control antibody, we observed a moderate enrichment in FOXA1 and OCT1 binding to DNA overlapping SNP rs10941679, but no difference between alleles in this cell line ( Figure S11 ). In addition, western blot analysis indicated that FOXA1 protein expression was restricted to the ER þ breast cancer cell lines analyzed, whereas OCT1 was more widely expressed ( Figure S12 ). FOXA1 is a pioneer factor and master regulator of ER activity due to its ability to open local chromatin and recruit ER to target gene promoters. 16 Notably, breast cancer-associated SNPs are enriched for FOXA1 binding 17 and several studies have linked cooperative binding of FOXA1, ER, and OCT1 to increased gene transcription. 18, 19 Consistent with our eQTL data, it is tempting to speculate that in specific ER þ cell subtypes and/or conditions, rs10941679 alters FOXA1 affinity and OCT1 recruitment leading to target gene activation.
In conclusion, we have provided evidence for at least three independent causal SNPs with effects on the risk of breast cancer at this locus. The minor g-allele of signal 1 SNP rs10941679 conferred a 15% increased risk of ER þ breast cancer and higher expression levels of the MRPS30 and FGF10 genes and was the most strongly associated SNP with MRPS30 expression in this 1 Mb region. MRPS30-also called PDCD9 (Programmed Cell Death protein 9)-encodes a mitochondrial ribosomal protein involved in apoptosis. 20 Although the role of mitochondria in apoptosis remains unclear, it is well established that cytochrome c and other pro-apoptotic proteins are released during cell death initiation. 20 Clearly, further investigation of the function of this protein is now merited. By contrast, FGF10 is an extensively studied gene with compelling data suggesting its involvement in breast tumorigenesis. FGF10 is a member of the fibroblast growth factor (FGF) family and encodes a glycoprotein that specifically binds to FGFR2 (splice FGFR2IIIb) to control signaling pathways including cell differentiation, proliferation, and apoptosis. 21 Variants regulating FGFR2 
